CNS Drugs

, Volume 5, Issue 3, pp 160–165 | Cite as

Central Post-Stroke Pain

Drug Treatment Options
  • David Bowsher
  • Turo Nurmikko
Disease Management


Central post-stroke pain (CPSP) follows stroke in up to 8% of patients. The pain is usually burning in character and is accompanied by a sensory deficit, particularly for nonpainful temperature and for pinprick (sharpness) sensations. About one-half of patients exhibit allodynia. The pain is not experienced until some months after the stroke in two-thirds of patients, so it is frequently the family doctor who is responsible for determining the diagnosis.

Conventional analgesics (including morphine) are largely ineffective, and precious time should not be wasted ‘trying’ them. The most effective treatment is with adrenergically active antidepressants (e.g. amitriptyline, nortriptyline, desipramine and maprotiline), in dosages increasing gradually from 10 or 25 to 50 or 75 mg/day. The sooner such treatment is commenced after pain onset, the better the prognosis.

In patients who do not respond to antidepressants, benefit may be obtained by the addition of mexiletine. Transcutaneous nerve stimulation or surgically implanted stimulators may help in recalcitrant cases.


Amitriptyline Mexiletine Maprotiline Transcutaneous Electrical Nerve Stimulation Postherpetic Neuralgia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andersen G, Vestergaard K, Ingeman-Nielsen M, et al. Incidence of central post-stroke pain. Pain 1995; 61: 187–94PubMedCrossRefGoogle Scholar
  2. 2.
    Bowsher DR, Foy PM, Shaw MDM. Central pain complicating infarction following subarachnoid haemorrhage. Br J Neurosurg 1989; 3: 435–43PubMedCrossRefGoogle Scholar
  3. 3.
    Cassinari V, Pagni CA. Central Pain. A neurosurgical survey. Cambridge (MA): Harvard University Press, 1969Google Scholar
  4. 4.
    Leijon G, Boivie J, Johansson I. Central post-stroke pain — neurological symptoms and pain characteristics. Pain 1989; 36: 13–25PubMedCrossRefGoogle Scholar
  5. 5.
    Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991; 47: 644–66PubMedGoogle Scholar
  6. 6.
    Dejerine J, Roussy J. Le syndrome thalamique. Rev Neurol 1906; 14: 521–32Google Scholar
  7. 7.
    Leijon G, Boivie J. Central post-stroke pain — a controlled trial of amitriptyline and carbamazepine. Pain 1989; 36: 27–36PubMedCrossRefGoogle Scholar
  8. 8.
    Bainton T, Fox M, Bowsher D, et al. A double-blind trial of naloxone in central post-stroke pain. Pain 1992; 48: 159–62PubMedCrossRefGoogle Scholar
  9. 9.
    Koppel BS. Amitriptyline in the treatment of thalamic pain. South Med J 1982; 79: 759–61CrossRefGoogle Scholar
  10. 10.
    Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671–3PubMedCrossRefGoogle Scholar
  11. 11.
    Leijon G, Boivie J. Pharmacological treatment of central pain. In: Casey KL, editor. Pain and central nervous system disease: the central pain syndromes. New York: Raven Press, 1991: 257–66Google Scholar
  12. 12.
    Ardid D, Guilbaud G. Antinociceptive effects of acute and ‘chronic’ injections of tricyclic antidepressant drugs in a new model of mononeuropathy in rats. Pain 1992; 49: 279–87PubMedCrossRefGoogle Scholar
  13. 13.
    Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427–32PubMedCrossRefGoogle Scholar
  14. 14.
    Lynch S, Max MB, Muir J, et al. Efficacy of antidepressants in relieving diabetic neuropathy pain: amitriptyline vs desipramine, and fluoxetine vs placebo [abstract]. Neurology 1990; 40 Suppl. 1: 437Google Scholar
  15. 15.
    Bowsher D. Acute shingles and postherpetic neuralgia: effects of acyclovir and outcome of treatment with amitriptyline. Br J Gen Pract 1992; 42: 244–6PubMedGoogle Scholar
  16. 16.
    Awerbuch GI, Sandyk R. Mexiletine for thalamic pain syndrome. Int J Neurosci 1990; 55: 129–33PubMedCrossRefGoogle Scholar
  17. 17.
    Backonja M, Arndt D, Gombar KA, et al. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 1994; 56: 51–7PubMedCrossRefGoogle Scholar
  18. 18.
    McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994; 59: 127–33PubMedCrossRefGoogle Scholar
  19. 19.
    Bowsher D. The management of central post-stroke pain. Postgrad Med J 1995; 71: 598–604PubMedCrossRefGoogle Scholar
  20. 20.
    Leijon G, Boivie J. Central post-stroke pain — the effect of high and low frequency TENS. Pain 1989; 38: 187–91PubMedCrossRefGoogle Scholar
  21. 21.
    Tsubokawa T, Katayama Y, Yamamoto T, et al. Chronic motor cortex stimulation in patients with thalamic pain. J Neurosurg 1993; 78: 393–401PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • David Bowsher
    • 1
  • Turo Nurmikko
    • 2
  1. 1.Pain Research InstituteWalton HospitalLiverpoolEngland
  2. 2.Pain Relief Service, The Walton Centre for Neurology and NeurosurgeryWalton HospitalLiverpoolEngland

Personalised recommendations